The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.
The conversation discusses a user's plan to inject NAD+ and GHK-Cu into their scalp to improve hair health, with concerns raised about the risks of infection and necrosis. Alternatives like finasteride, dutasteride, microneedling, oral minoxidil, and scalp massages are suggested.
The user experienced significant hair regrowth and increased density after six months of using oral minoxidil and finasteride chewables, despite going through a secondary shedding phase. The only side effect mentioned was restlessness, and the user feels healthier overall.
A user experienced increased hair density loss after 4 months on dutasteride combined with finasteride. They are also using topical dutasteride with azelaic acid and alfatradiol but cannot tolerate antiandrogens like RU58841 due to headaches.
The conversation discusses a new 0.3% tretinoin topical launched by MinoxidilMax for mixing with other solutions, with some users expressing concern about potential skin irritation compared to lower concentrations. MinoxidilMax has also released other products like topical Dutasteride and RU58841.
Finasteride can cause gynecomastia due to hormonal imbalances, and using an aromatase inhibitor like anastrozole can help manage these side effects. It's important to work with an endocrinologist to address these issues safely.
A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The user is considering switching from finasteride to dutasteride due to side effects like brain fog and lower libido. They experienced hair regrowth with finasteride but are concerned about potential side effects of dutasteride.
The user experienced positive hair growth with finasteride but developed gut issues, dry skin, thinning eyebrows, fatigue, low libido, and erection difficulties after stopping it. They are seeking advice on whether to resume finasteride or stay off it to recover.
Taking topical minoxidil orally for hair loss treatment, discussing safety, dosing, side effects, and FAQs. Users express concerns about safety and potential heart damage, while others share experiences and results.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.
Finasteride can increase estrogen levels, causing dizziness and nausea. Users discuss adjusting treatment and diet, and explore alternatives for hair loss management.
A user discusses a hair loss treatment combining minoxidil and tretinoin, noting it may enhance absorption. Some users express interest and share positive experiences, while others question its effectiveness without medical evidence.
The user is using a 5% minoxidil solution with low propylene glycol and 1 mg of oral finasteride daily but is still experiencing hair shedding, especially at the temples and front. They are concerned about absorption issues and considering adding tretinoin to improve results.
User experienced severe allergic reactions and liver issues after a hair transplant, likely due to antibiotics and medications. Despite trying Minoxidil, the user faced further complications and is now seeking medical advice for potential future transplants.
The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.
The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.
The user is concerned about the interaction between dutasteride and ketoconazole, leading them to stop using ketoconazole shampoo, which has resulted in an oily and painful scalp. They are unsure whether ketoconazole increases or decreases the potency of dutasteride.
A 23-year-old male experienced nipple sensitivity after taking 0.5 mg finasteride for 2.5 months, with blood tests showing increased testosterone and estrogen levels. He stopped finasteride temporarily and seeks advice to prevent gynecomastia.
Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.
The user is considering blood tests to understand their receding hairline and is exploring brewer's yeast for its biotin content. They have been using topical Minoxidil, biotin, collagen, and microneedling, but are avoiding oral Finasteride and Dutasteride.
A user experienced chest discomfort after taking finasteride for hair loss and is concerned about whether it is a side effect or an allergy. They are advised to consult a doctor and consider other hair loss treatments if necessary.
Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.